Medical Care

Global Benign Prostate Hyperplasia Drugs Market Insights, Forecast to 2030

The goal of Benign prostate hyperplasia drugs is to reduce morbidity and prevent complications.Agents used include alpha-adrenergic blockers, 5-alpha-reductase inhibitors, phosphodiesterase -5 inhibitors and various combinations.
Market Analysis and Insights: Global Benign Prostate Hyperplasia Drugs Market
The global Benign Prostate Hyperplasia Drugs market is projected to grow from US$ 3452.6 million in 2024 to US$ 4195.1 million by 2030, at a Compound Annual Growth Rate (CAGR) of 3.3% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Benign Prostate Hyperplasia Drugs market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Benign Prostate Hyperplasia Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Benign Prostate Hyperplasia Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Benign Prostate Hyperplasia Drugs revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Benign Prostate Hyperplasia Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Benign Prostate Hyperplasia Drugs revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Sanofi
Coloplast
Pfizer
Merck
GlaxoSmithKline
Eli Lilly and Company
Abbott Laboratories
Teva Pharmaceuticals
Allergan
Boehringer Ingelheim
Segment by Type
Alpha Blocker
5-Alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Others
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Benign Prostate Hyperplasia Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Benign Prostate Hyperplasia Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Benign Prostate Hyperplasia Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Alpha Blocker
1.2.3 5-Alpha Reductase Inhibitor
1.2.4 Phosphodiesterase-5 Inhibitor
1.2.5 Others
1.3 Market by Application
1.3.1 Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Benign Prostate Hyperplasia Drugs Market Perspective (2019-2030)
2.2 Global Benign Prostate Hyperplasia Drugs Growth Trends by Region
2.2.1 Benign Prostate Hyperplasia Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Benign Prostate Hyperplasia Drugs Historic Market Size by Region (2019-2024)
2.2.3 Benign Prostate Hyperplasia Drugs Forecasted Market Size by Region (2025-2030)
2.3 Benign Prostate Hyperplasia Drugs Market Dynamics
2.3.1 Benign Prostate Hyperplasia Drugs Industry Trends
2.3.2 Benign Prostate Hyperplasia Drugs Market Drivers
2.3.3 Benign Prostate Hyperplasia Drugs Market Challenges
2.3.4 Benign Prostate Hyperplasia Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Benign Prostate Hyperplasia Drugs by Players
3.1.1 Global Benign Prostate Hyperplasia Drugs Revenue by Players (2019-2024)
3.1.2 Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Benign Prostate Hyperplasia Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Benign Prostate Hyperplasia Drugs, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Benign Prostate Hyperplasia Drugs Market Concentration Ratio
3.4.1 Global Benign Prostate Hyperplasia Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Benign Prostate Hyperplasia Drugs Revenue in 2023
3.5 Global Key Players of Benign Prostate Hyperplasia Drugs Head office and Area Served
3.6 Global Key Players of Benign Prostate Hyperplasia Drugs, Product and Application
3.7 Global Key Players of Benign Prostate Hyperplasia Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Benign Prostate Hyperplasia Drugs Breakdown Data by Type
4.1 Global Benign Prostate Hyperplasia Drugs Historic Market Size by Type (2019-2024)
4.2 Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Type (2025-2030)
5 Benign Prostate Hyperplasia Drugs Breakdown Data by Application
5.1 Global Benign Prostate Hyperplasia Drugs Historic Market Size by Application (2019-2024)
5.2 Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Benign Prostate Hyperplasia Drugs Market Size (2019-2030)
6.2 North America Benign Prostate Hyperplasia Drugs Market Size by Type
6.2.1 North America Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024)
6.2.2 North America Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030)
6.2.3 North America Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
6.3 North America Benign Prostate Hyperplasia Drugs Market Size by Application
6.3.1 North America Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024)
6.3.2 North America Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030)
6.3.3 North America Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
6.4 North America Benign Prostate Hyperplasia Drugs Market Size by Country
6.4.1 North America Benign Prostate Hyperplasia Drugs Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Benign Prostate Hyperplasia Drugs Market Size by Country (2019-2024)
6.4.3 North America Benign Prostate Hyperplasia Drugs Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Benign Prostate Hyperplasia Drugs Market Size (2019-2030)
7.2 Europe Benign Prostate Hyperplasia Drugs Market Size by Type
7.2.1 Europe Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024)
7.2.2 Europe Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030)
7.2.3 Europe Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
7.3 Europe Benign Prostate Hyperplasia Drugs Market Size by Application
7.3.1 Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024)
7.3.2 Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030)
7.3.3 Europe Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
7.4 Europe Benign Prostate Hyperplasia Drugs Market Size by Country
7.4.1 Europe Benign Prostate Hyperplasia Drugs Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Benign Prostate Hyperplasia Drugs Market Size by Country (2019-2024)
7.4.3 Europe Benign Prostate Hyperplasia Drugs Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Benign Prostate Hyperplasia Drugs Market Size (2019-2030)
8.2 China Benign Prostate Hyperplasia Drugs Market Size by Type
8.2.1 China Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024)
8.2.2 China Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030)
8.2.3 China Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
8.3 China Benign Prostate Hyperplasia Drugs Market Size by Application
8.3.1 China Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024)
8.3.2 China Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030)
8.3.3 China Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Benign Prostate Hyperplasia Drugs Market Size (2019-2030)
9.2 Asia Benign Prostate Hyperplasia Drugs Market Size by Type
9.2.1 Asia Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024)
9.2.2 Asia Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030)
9.2.3 Asia Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
9.3 Asia Benign Prostate Hyperplasia Drugs Market Size by Application
9.3.1 Asia Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024)
9.3.2 Asia Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030)
9.3.3 Asia Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
9.4 Asia Benign Prostate Hyperplasia Drugs Market Size by Region
9.4.1 Asia Benign Prostate Hyperplasia Drugs Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Benign Prostate Hyperplasia Drugs Market Size by Region (2019-2024)
9.4.3 Asia Benign Prostate Hyperplasia Drugs Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Type
10.2.1 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Application
10.3.1 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Country
10.4.1 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Benign Prostate Hyperplasia Drugs Introduction
11.1.4 Sanofi Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.1.5 Sanofi Recent Developments
11.2 Coloplast
11.2.1 Coloplast Company Details
11.2.2 Coloplast Business Overview
11.2.3 Coloplast Benign Prostate Hyperplasia Drugs Introduction
11.2.4 Coloplast Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.2.5 Coloplast Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Benign Prostate Hyperplasia Drugs Introduction
11.3.4 Pfizer Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.3.5 Pfizer Recent Developments
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Benign Prostate Hyperplasia Drugs Introduction
11.4.4 Merck Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.4.5 Merck Recent Developments
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Benign Prostate Hyperplasia Drugs Introduction
11.5.4 GlaxoSmithKline Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.5.5 GlaxoSmithKline Recent Developments
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Company Details
11.6.2 Eli Lilly and Company Business Overview
11.6.3 Eli Lilly and Company Benign Prostate Hyperplasia Drugs Introduction
11.6.4 Eli Lilly and Company Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.6.5 Eli Lilly and Company Recent Developments
11.7 Abbott Laboratories
11.7.1 Abbott Laboratories Company Details
11.7.2 Abbott Laboratories Business Overview
11.7.3 Abbott Laboratories Benign Prostate Hyperplasia Drugs Introduction
11.7.4 Abbott Laboratories Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.7.5 Abbott Laboratories Recent Developments
11.8 Teva Pharmaceuticals
11.8.1 Teva Pharmaceuticals Company Details
11.8.2 Teva Pharmaceuticals Business Overview
11.8.3 Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Introduction
11.8.4 Teva Pharmaceuticals Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.8.5 Teva Pharmaceuticals Recent Developments
11.9 Allergan
11.9.1 Allergan Company Details
11.9.2 Allergan Business Overview
11.9.3 Allergan Benign Prostate Hyperplasia Drugs Introduction
11.9.4 Allergan Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.9.5 Allergan Recent Developments
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Company Details
11.10.2 Boehringer Ingelheim Business Overview
11.10.3 Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Introduction
11.10.4 Boehringer Ingelheim Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.10.5 Boehringer Ingelheim Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 2. Key Players of Alpha Blocker
Table 3. Key Players of 5-Alpha Reductase Inhibitor
Table 4. Key Players of Phosphodiesterase-5 Inhibitor
Table 5. Key Players of Others
Table 6. Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 7. Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Benign Prostate Hyperplasia Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Benign Prostate Hyperplasia Drugs Market Share by Region (2019-2024)
Table 10. Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Benign Prostate Hyperplasia Drugs Market Share by Region (2025-2030)
Table 12. Benign Prostate Hyperplasia Drugs Market Trends
Table 13. Benign Prostate Hyperplasia Drugs Market Drivers
Table 14. Benign Prostate Hyperplasia Drugs Market Challenges
Table 15. Benign Prostate Hyperplasia Drugs Market Restraints
Table 16. Global Benign Prostate Hyperplasia Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Benign Prostate Hyperplasia Drugs Revenue Share by Players (2019-2024)
Table 18. Global Top Benign Prostate Hyperplasia Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostate Hyperplasia Drugs as of 2023)
Table 19. Global Benign Prostate Hyperplasia Drugs Industry Ranking 2022 VS 2023 VS 2024
Table 20. Global 5 Largest Players Market Share by Benign Prostate Hyperplasia Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 21. Global Key Players of Benign Prostate Hyperplasia Drugs, Headquarters and Area Served
Table 22. Global Key Players of Benign Prostate Hyperplasia Drugs, Product and Application
Table 23. Global Key Players of Benign Prostate Hyperplasia Drugs, Product and Application
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Type (2019-2024)
Table 27. Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Type (2025-2030)
Table 29. Global Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Benign Prostate Hyperplasia Drugs Revenue Share by Application (2019-2024)
Table 31. Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Benign Prostate Hyperplasia Drugs Revenue Share by Application (2025-2030)
Table 33. North America Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 34. North America Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030) & (US$ Million)
Table 35. North America Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 36. North America Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030) & (US$ Million)
Table 37. North America Benign Prostate Hyperplasia Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. North America Benign Prostate Hyperplasia Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 39. North America Benign Prostate Hyperplasia Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 40. Europe Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 41. Europe Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030) & (US$ Million)
Table 42. Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 43. Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030) & (US$ Million)
Table 44. Europe Benign Prostate Hyperplasia Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Europe Benign Prostate Hyperplasia Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 46. Europe Benign Prostate Hyperplasia Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 47. China Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 48. China Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030) & (US$ Million)
Table 49. China Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 50. China Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030) & (US$ Million)
Table 51. Asia Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 52. Asia Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030) & (US$ Million)
Table 53. Asia Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 54. Asia Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030) & (US$ Million)
Table 55. Asia Benign Prostate Hyperplasia Drugs Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 56. Asia Benign Prostate Hyperplasia Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 57. Asia Benign Prostate Hyperplasia Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
Table 63. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 65. Sanofi Company Details
Table 66. Sanofi Business Overview
Table 67. Sanofi Benign Prostate Hyperplasia Drugs Product
Table 68. Sanofi Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
Table 69. Sanofi Recent Developments
Table 70. Coloplast Company Details
Table 71. Coloplast Business Overview
Table 72. Coloplast Benign Prostate Hyperplasia Drugs Product
Table 73. Coloplast Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
Table 74. Coloplast Recent Developments
Table 75. Pfizer Company Details
Table 76. Pfizer Business Overview
Table 77. Pfizer Benign Prostate Hyperplasia Drugs Product
Table 78. Pfizer Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
Table 79. Pfizer Recent Developments
Table 80. Merck Company Details
Table 81. Merck Business Overview
Table 82. Merck Benign Prostate Hyperplasia Drugs Product
Table 83. Merck Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
Table 84. Merck Recent Developments
Table 85. GlaxoSmithKline Company Details
Table 86. GlaxoSmithKline Business Overview
Table 87. GlaxoSmithKline Benign Prostate Hyperplasia Drugs Product
Table 88. GlaxoSmithKline Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
Table 89. GlaxoSmithKline Recent Developments
Table 90. Eli Lilly and Company Company Details
Table 91. Eli Lilly and Company Business Overview
Table 92. Eli Lilly and Company Benign Prostate Hyperplasia Drugs Product
Table 93. Eli Lilly and Company Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
Table 94. Eli Lilly and Company Recent Developments
Table 95. Abbott Laboratories Company Details
Table 96. Abbott Laboratories Business Overview
Table 97. Abbott Laboratories Benign Prostate Hyperplasia Drugs Product
Table 98. Abbott Laboratories Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
Table 99. Abbott Laboratories Recent Developments
Table 100. Teva Pharmaceuticals Company Details
Table 101. Teva Pharmaceuticals Business Overview
Table 102. Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Product
Table 103. Teva Pharmaceuticals Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
Table 104. Teva Pharmaceuticals Recent Developments
Table 105. Allergan Company Details
Table 106. Allergan Business Overview
Table 107. Allergan Benign Prostate Hyperplasia Drugs Product
Table 108. Allergan Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
Table 109. Allergan Recent Developments
Table 110. Boehringer Ingelheim Company Details
Table 111. Boehringer Ingelheim Business Overview
Table 112. Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Product
Table 113. Boehringer Ingelheim Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
Table 114. Boehringer Ingelheim Recent Developments
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 2. Global Benign Prostate Hyperplasia Drugs Market Share by Type: 2023 VS 2030
Figure 3. Alpha Blocker Features
Figure 4. 5-Alpha Reductase Inhibitor Features
Figure 5. Phosphodiesterase-5 Inhibitor Features
Figure 6. Others Features
Figure 7. Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 8. Global Benign Prostate Hyperplasia Drugs Market Share by Application: 2023 VS 2030
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Other Case Studies
Figure 12. Benign Prostate Hyperplasia Drugs Report Years Considered
Figure 13. Global Benign Prostate Hyperplasia Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Benign Prostate Hyperplasia Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Benign Prostate Hyperplasia Drugs Market Share by Region: 2023 VS 2030
Figure 16. Global Benign Prostate Hyperplasia Drugs Market Share by Players in 2023
Figure 17. Global Top Benign Prostate Hyperplasia Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostate Hyperplasia Drugs as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Benign Prostate Hyperplasia Drugs Revenue in 2023
Figure 19. North America Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
Figure 21. North America Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
Figure 22. North America Benign Prostate Hyperplasia Drugs Market Share by Country (2019-2030)
Figure 23. United States Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Benign Prostate Hyperplasia Drugs Market Size YoY (2019-2030) & (US$ Million)
Figure 26. Europe Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
Figure 27. Europe Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
Figure 28. Europe Benign Prostate Hyperplasia Drugs Market Share by Country (2019-2030)
Figure 29. Germany Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. France Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. U.K. Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Italy Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Russia Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Nordic Countries Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. China Benign Prostate Hyperplasia Drugs Market Size YoY (2019-2030) & (US$ Million)
Figure 36. China Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
Figure 37. China Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
Figure 38. Asia Benign Prostate Hyperplasia Drugs Market Size YoY (2019-2030) & (US$ Million)
Figure 39. Asia Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
Figure 40. Asia Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
Figure 41. Asia Benign Prostate Hyperplasia Drugs Market Share by Region (2019-2030)
Figure 42. Japan Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. South Korea Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. China Taiwan Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Southeast Asia Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. India Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Australia Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size YoY (2019-2030) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
Figure 50. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
Figure 51. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Share by Country (2019-2030)
Figure 52. Brazil Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 53. Mexico Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. Turkey Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 55. Saudi Arabia Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 56. Israel Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 57. GCC Countries Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 58. Sanofi Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
Figure 59. Coloplast Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
Figure 60. Pfizer Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
Figure 61. Merck Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
Figure 62. GlaxoSmithKline Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
Figure 63. Eli Lilly and Company Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
Figure 64. Abbott Laboratories Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
Figure 65. Teva Pharmaceuticals Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
Figure 66. Allergan Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
Figure 67. Boehringer Ingelheim Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies